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Abstract
Bacterial meningitis is a complex disorder in which injury is caused,
in part, by the causative organism and, in part, by the host’s own
inflammatory response. Macrophage migration inhibitory factor
(MIF) is a pro-inflammatory cytokine and a neuro-endocrine
mediator that might play a role in pneumococcal meningitis. Here,
we discuss the role of MIF in infection, the brain, and cortico-
steroids and conclude that experimental meningitis studies have to
determine whether MIF is a potential target for adjunctive therapy
in pneumococcal meningitis.
In the previous issue of Critical Care, Ostergaard and Benfield
[1] described cerebrospinal fluid macrophage migration
inhibitory factor (MIF) levels in 171 patients with clinically
suspected meningitis at time of admission. Elevated MIF levels
were observed in patients with purulent meningitis with known
bacterial aetiology versus patients with viral infection, no
known aetiology, or no meningitis. Cerebrospinal fluid MIF
levels had limited predictive value in distinguishing between
life-threatening bacterial meningitis and other aetiologies when
evaluating a patient suspected of having meningitis and
therefore cannot be used for diagnostic purposes. This study
did, however, present several interesting findings: among the
patients with purulent meningitis, elevated cerebrospinal fluid
MIF levels were associated with increased need for assisted
ventilation and with impaired consciousness. Furthermore,
patients with pneumococcal meningitis in particular had
elevated cerebrospinal fluid MIF levels.
MIF is a multi-functional protein that acts both as a cytokine
[2] and a neuro-endocrine mediator [3]. It is abundantly
expressed in various cell types, including cells of the immune
system, cells of the central nervous system, epithelial cells (of
the skin, kidney, and liver), pancreatic beta cells, cardiac
myocytes, endothelial cells, and fibroblasts [4]. MIF has been
reported to play a role in the pathogenesis of several inflam-
matory and infectious diseases, including sepsis and septic
shock [5].
As a pro-inflammatory cytokine, MIF is produced in response
to endotoxin, exotoxins, Gram-positive and Gram-negative
bacteria, mycobacteria, malaria pigment, and the pro-
inflammatory cytokines tumour necrosis factor-alpha (TNF-α)
and interferon-gamma [4,6]. In macrophages, MIF acts in an
autocrine fashion, leading to the production of pro-
inflammatory cytokines interleukin-8 (IL-8), IL-1β, TNF-α, and
nitric oxide [7]. In addition, MIF enhances Toll-like receptor-4
expression on the macrophage surface, increases phago-
cytosis and intracellular killing, and inhibits apoptosis [6].
Furthermore, MIF stimulates T-lymphocyte activation and
B-lymphocyte antibody production [5].
As a neuro-endocrine mediator, MIF is secreted by anterior
pituitary cells in response to low serum glucocorticoids levels,
thereby overriding the inhibitory effect of glucocorticoids on
the immune response [3]. MIF selectively limits corticosteroid-
mediated immune depression without influencing  other
physiological effects of glucocorticoids during the stress
response. However, at high glucocorticoid levels, MIF is no
longer able to effectively limit corticosteroid-mediated path-
ways, thereby preventing an excessive and potentially harmful
immune response [5].
Bacterial meningitis occurs in between 2.6 and 6 persons per
100,000 per year in developed countries and may be up to
10 times more prevalent in some areas of developing countries
[8]. Vaccination strategies have substantially changed the
epidemiology of bacterial meningitis during the past two
decades [9]. Today, bacterial meningitis strikes more adults
than children and the most common causative pathogen is
Streptococcus pneumoniae. Despite advances in medical
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care, the mortality due to pneumococcal meningitis ranges
from 16% to 37% and neurological sequelae are estimated
to occur in 30% to 52% of surviving adults [10].
Central nervous system inflammation of any kind is poorly
tolerated. Experimental meningitis models have shown that
inflammatory responses within the enclosed spaces of the
brain and spinal cord lead to destructive secondary effects
[11]. Pharmacological attempts to modulate this inflammatory
response may be essential for the development of new
therapeutic strategies in the treatment of this life-threatening
disease. Currently, dexamethasone is the only accepted, and
clinically proven, adjunctive therapy for the treatment of
patients with bacterial meningitis [12,13]. The exact working
mechanism by which dexamethasone prevents deaths in
bacterial meningitis remains unknown [14]. Despite these
encouraging results of adjunctive dexamethasone, the high
mortality rate among patients with meningitis stresses the
need for new adjunctive treatment strategies.
In patients with sepsis, elevated MIF levels were associated
with increased mortality [15]. Corticosteroid therapy has been
used in varied doses for sepsis and related syndromes without
any clear reduction of mortality. However, since 1998, sepsis
studies have consistently used prolonged low-dose cortico-
steroid therapy, and analysis of this subgroup suggests a
beneficial drug effect on short-term outcome [16]. Patients with
septic shock who are treated with high-dose corticosteroids
have lower serum MIF levels compared to those not treated
with high-dose corticosteroids [15]. In a mouse model of
endotoxin- or bacterial peritonitis-induced septic shock, neutra-
lizing antibodies to MIF increased survival [2,6].
In conclusion, MIF appears to play a role in central nervous
system infections and has an interaction with therapeutic
corticosteroids. Therefore, MIF regulation may be involved in
the mechanism by which early dexamethasone treatment of
bacterial meningitis in adults improves outcome. Studies in
animal models of pneumococcal meningitis will have to
determine whether MIF is a potential target for adjunctive
therapy in the future.
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